The PREVALENT initiative brings together 15 partners across 9 European countries who have joined forces to implement a novel European Research Infrastructure for pre-clinical, environmental, virtual integrative assessments, and therapeutics development.
Participating institutions and companies
Czech Centre for Phenogenomics
Ludwig-Maximilians-Universität München
Biomedical Sciences Research Centre Alexander Fleming
The Institut Clinique de la Souris – ICS (Mouse Clinical Institute – MCI)
Medical Research Council Harwell
The University of Sheffield
Helmholtz Zentrum Muenchen – Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Université du Luxembourg
The National Centre for Biotechnology (Centro Nacional de Biotecnología, CNB)
Institute for Advanced Chemistry of Catalonia
Université de Liège
Masaryk University
Institute of Organic Chemistry and Biochemistry
Erasmus Universitair Medisch Centrum Rotterdam
APIGENEX s.r.o.
Biomedcode Hellas SA
News & Events
8th September
Variability in Genome Editing Outcomes Challenges for Research Reproducibility and Clinical Safety
Researchers at MRC Harwell, alongside their colleagues at Université de Strasbourg and Great Ormond Street Institute of Child Health, have published a review in Molecular Therapy (https://www.sciencedirect.com/science/article/pii/S1525001620301490?via%3Dihub). The review explores the reliability and challenges of genome editing application in both research and in clinic.
Show detail
September 17 – 18, 2020 | Prague, Czech Republic
2nd CCP Phenogenomics Conference 2020
The first day will be devoted to the theme “From chemistry via preclinical pipeline to therapeutics“, which emphasizes the translation of the basic research into the application. The second day is specifically devoted to CCP’s users and cooperation partners working in the field of immunology, hematology, genetic base of diseases, and neurobiology.
Show detail